首页> Cancer medicine> Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.

Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Doris K,Hansen

第一单位： Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.

作者： Doris K,Hansen ^[1] ; Santosh,Gautam ^[2] ; Marie-Hélène,Lafeuille ^[3] ; Carmine,Rossi ^[3] ; Bronwyn,Moore ^[3] ; Anabelle,Tardif-Samson ^[3] ; Philippe,Thompson-Leduc ^[3] ; Alex Z,Fu ^[2] ; Annelore,Cortoos ^[2] ; Shuchita,Kaila ^[2] ; Rafael,Fonseca ^[4]

作者单位： Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA. ^[1] Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA. ^[2] Analysis Group, Inc., Montréal, Quebec, Canada. ^[3] Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA. ^[4]

关键词 bortezomib daratumumab drug therapy health care hematologic diseases multiple myeloma observational study outcome assessment